-
Sector Analysis
Spinal Non-Fusion Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Spinal Non-Fusion Market Report Overview The spinal non-fusion market size was $884.8 million in 2023. The market is expected to grow at a CAGR of more than 5% during 2023-2033. Spinal non-fusion surgery is performed to treat spinal instability, degenerative disc disorder, and spinal stenosis while preserving the spine's normal motion, load bearing, and shock absorption capacity. Spinal non-fusion surgery also provides pain relief without major anatomical removal. Spinal Non-Fusion Market Outlook, 2023-2033 ($ Million) Buy the Full Report for...
-
Product Insights
JDA – Jaipur IPD Tower and Institute of Cardiology – Rajasthan
Equip yourself with the essential tools needed to make informed and profitable decisions with our JDA - Jaipur IPD Tower and Institute of Cardiology - Rajasthan report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Company Profile
Vaxcyte Inc – Company Profile
Vaxcyte Inc (Vaxcyte), formerly SutroVax Inc, is a clinical-stage vaccine innovation company. It develops novel vaccines to prevent and treat infectious diseases. The company's pipeline products include VAX-24, an invasive pneumococcal disease (IPD); VAX-XP, a superior conjugate vaccine against IPD; VAX-A1, group A strep infections in children; and VAX-PG, a novel protein vaccine, targeting periodontitis in adults. It utilizes a cell-free protein synthesis platform to design and produce protein carriers and antigens, the critical building blocks of vaccines. The company...
Add to Basket -
Government & Regulation
Smart Grid Policy Handbook 2019
“Smart Grid Policy Handbook 2019” is the latest policy report from GlobalData, which offers comprehensive information on major policies governing smart grid in different countries. The report covers sixteen key countries, providing the current scenario and future plans in implementing smart grid technology, giving a fair idea of overall growth potential of the smart grid industry in each of these countries, and also globally. Countries covered in the handbook include – the US, Canada, Mexico, Brazil, China, Japan, Australia, Republic...
-
Sector Analysis
Pneumococcal Vaccines – Epidemiology Forecast to 2028
Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk...
-
Sector Analysis
Pneumococcal Vaccines – Epidemiology Forecast in Asia-Pacific Markets to 2028
Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk...
-
Sector Analysis
Pneumococcal Vaccines – Global Drug Forecast and Market Analysis to 2028
Streptococcus pneumoniae (S. pneumoniae), a Gram-positive bacterial respiratory pathogen, is a leading cause of mortality and morbidity globally and is responsible for a large proportion of deaths due to infectious disease. In 2005, The World Health Organization (WHO) estimated 1.6 million deaths were caused by S. pneumoniae annually, including 0.7-1 million children under the age of 5 years. In Europe and the US, the annual incidence of pneumococcal disease ranges from 10 to 100 per 100,000 population. S. pneumoniae causes...